Role of taxanes in the combined modality treatment of patients with locally advanced non-small cell lung cancer

Expert Opinion on Pharmacotherapy

Volumn 2, Issue 6, 2001, Pages 963-974

  Choy, H ^a   Pyo, H ^a   Kim, J S ^a   MacRae, R ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Combined modality treatment; Docetaxel; Lung cancer; Paclitaxel; Radiotherapy; Taxanes

Indexed keywords

AMIFOSTINE; BMS 184476; BMS 185660; BMS 188797; CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; MITOMYCIN C; NAVELBINE; PACLITAXEL; PLATINUM; TAXANE DERIVATIVE; TAXOLTERE METRO; TAXOPREXIN; UNCLASSIFIED DRUG; VINBLASTINE; VINDESINE;

ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL TRIAL; DATA ANALYSIS; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG RESPONSE; ESOPHAGITIS; HUMAN; INOPERABLE CANCER; LUNG NON SMALL CELL CANCER; METASTASIS; PLANT; REVIEW; SURVIVAL RATE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BRIDGED COMPOUNDS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS; COMBINED MODALITY THERAPY; GUIDELINES; LUNG NEOPLASMS; MULTICENTER STUDIES; NEOPLASM STAGING; PACLITAXEL; TAXOIDS; TREATMENT OUTCOME;

EID: 0034864647     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2.6.963     Document Type: Review

References (98)

1. Cancer Statistics, 2000
2. Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small cell lung cancer: Radiation Therapy Oncology Group Protocol 91-06
3. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer
4. Five-year results: Phase III trial of regionally advanced unresectable non-small cell lung cancer, RTOG 8808, ECOG 4588, SWOG 8992
5. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: Preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer
6. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: First analysis of a randomized trial in 353 patients
7. Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small cell lung cancer
8. Hyperfractionated radiation therapy with or without concurrent low dose daily carboplatin/etoposide for stage III non-small cell lung cancer. A randomized study
9. Impact of adding concurrent chemotherapy to hyperfractionated radiotherapy for locally advanced non-small cell lung cancer (NSCLC): Comparison of RTOG 83-11 and RTOG 91-06
10. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer
11. A randomised Phase III study of accelerated or standard fraction radiotherapy with or without concurrent carboplatin in inoperable non-small cell lung cancer: Final report of an Australian multi-centre trial
12. Multimodality therapy in stage III non-small cell lung cancer
13. Multidisciplinary approach to potentially curable non-small cell carcinoma of the lung
14. Improved survival in stage III non-small-cell lung cancer: Seven-year follow-up of Cancer and Leukemia Group B (CALGB) 8433 trial
15. Final results of Phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group
16. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer
17. Phase III comparison of sequential vs. concurrent chemo-radiation for pts with unresected stage III non-small cell lung cancer (NSCLC): Report of Radiation Therapy Oncology Group (RTOG) 9410
18. Non-Small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials
19. Paclitaxel (Taxol)
20. Docetaxel: An active new drug for treatment of advanced epithelial ovarian cancer
21. Paclitaxel and carboplatin with and without filgrastim support in patients with metastatic non-small cell lung cancer
22. Docetaxel (Taxotere) is active in non-small-cell lung cancer: A Phase II trial of the EORTC Early Clinical Trials Group (ECTG)
23. Taxol binds to cellular microbutules
24. Taxol binds to polymerized tubulin in vitro
25. Relationships between the structure of Taxol analogues and their antimitotic activity
26. Taxol stabilizes microtubules in mouse fibroblast cells
27. Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel
28. Role of reoxygenation in induction of enhancement of tumor radioresponse by paclitaxel
29. Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: The Eastern Cooperative Oncology Group results
30. Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer
31. Phase I trial of outpatient weekly paclitaxel and concurrent radiation therapy for advanced non-small-cell lung cancer
32. Phase II trial of weekly paclitaxel and concurrent radiation therapy for locally advanced non-small cell lung cancer
33. Multiinstitutional Phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer
34. A Phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small-cell lung cancer (a Vanderbilt Cancer Center Affiliate Network Study)
35. Esophagitis in combined modality therapy for locally advanced non-small cell lung cancer
36. Induction carboplatin/paclitaxel followed by concurrent carboplatin/paclitaxel and dose-escalating conformal thoracic radiation therapy in unresectable stage IIIA/B nonsmall cell lung carcinoma: A modified Phase I trial
37. Induction (I) and concurrent (C) carboplatin/paclitaxel (C/P) with dose-escalated thoracic conformal radiotherapy (TCRT) in stage IIIA/B non-small cell lung cancer (NSCLC): A Phase I/II trial
38. Twice-weekly paclitaxel and weekly carboplatin with concurrent thoracic radiation followed by carboplatin/paclitaxel consolidation for stage III non-small-cell lung cancer: A California Cancer Consortium Phase II Trial
39. Preliminary results of weekly paclitaxel (P) and continuous hyperfractionated accelerated radiotherapy (CHART) in locally advanced non-small cell lung cancer (NSCLC)
40. Twice-weekly paclitaxel and radiation for stage III non-small cell lung cancer
41. Pulsed paclitaxel radiosensitization for thoracic malignancy: A therapeutic approach based on pre-clinical research of human lung cancer cells
42. Paclitaxel and concurrent radiotherapy in locally advanced non-small cell lung cancer: The Canadian Experience
43. Daily paclitaxel and thoracic radiation therapy for stage II/III non-small cell lung cancer
44. Combined modality therapy for unresectable stage III non-small cell lung cancer
45. Induction chemotherapy with paclitaxel (P) and carboplatin (C) followed by concurrent thoracic radiation and weekly PC for patients with unresectable stage III non-small cell lung cancer (NSCLC): Preliminary trial by Cancer and Leukemia Group B
46. Induction paclitaxel and carboplatin (CBDCA) followed by concurrent chemoradiation (TRT-CT) in unresectable, locally advanced non-small cell lung carcinoma: Report of Fox Chase Cancer Center 94-001
47. Paclitaxel in combination chemotherapy with radiotherapy in patients with unresectable stage III non-small-cell lung cancer
48. CALGB study 9431: A randomized Phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy (Ind CT) and concomitant chemoradiotherapy (XRT) for unresectable stage III lung cancer (NSCLC)
49. Paxlitaxel and carboplatin followed by concomitant paclitaxel, cisplatin, and radiotherapy for inoperable stage III non-small cell lung cancer
50. A Phase II trial of amifostine with paclitaxel, carboplatin and concurrent radiation therapy for unresectable non-small cell lung cancer
51. An update on North American randomized studies in non-small cell lung cancer
52. Combining taxanes with radiation for solid tumors
53. A CALGB randomized Phase II study of gemcitabine or paclitaxel or vinorelbine with cisplatin as induction chemotherapy (Inc CT) and concomitant chemoradiotherapy (XRT) in stage IIIB non-small cell lung data (CALGB study #9431)
54. Combined chemotherapy radiation therapy treatment in unresectable non-small cell lung cancer Radiation Therapy Oncology Group (RTOG) experience
55. Incorporation of paclitaxel and carboplatin in combined modality therapy for locally advanced non-small cell lung cancer
56. Weekly paclitaxel-based combined modality therapy in stage III non-small cell lung cancer: The sequential trial
57. Docetaxel (Taxotere): A review of preclinical and clinical experience. Part I: Preclinical experience
58. Preclinical evaluation of docetaxel (Taxotere)
59. Effects of Taxotere on murine and human tumour cell lines
60. Bcl2 is the guardian of microtubule integrity
61. Comparative antitumor efficacy of docetaxel and paclitaxel in nude mice bearing human tumor xenografts that overexpress the multidrug resistance protein
62. Phase II trials of taxotere in patients with non-small-cell lung cancer
63. Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer
64. Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer
65. Taxotere: Clinical trials in non-small cell lung cancer
66. Activity of docetaxel in platinum-treated non-small-cell lung cancer: Results of a Phase II multicenter trial
67. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy
68. Randomized Phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens
69. Concurrent conventionally fractionated radiotherapy and weekly docetaxel in the treatment of stage IIIb non-small-cell lung carcinoma
70. A Phase I/II study of docetaxel (Taxotere) combined with concurrent radiation therapy in locally advanced non-small cell lung cancer (NSCLC)
71. Phase I trial of outpatient weekly docetaxel (DTX) Carboplatin (CBDCA) and concurrent thoracic radiation therapy (TRT) for stage III unresectable non-small-cell lung cancer: A Vanderbilt Cancer Center Affiliate Network (VCCAN) Trial
72. Phase I study of weekly docetaxel (DTX) and carboplatin (CBDCA) with concurrent thoracic radiotherapy (TRT) for stage III non-small cell lung cancer (NSCLC)
73. A phase I/II study of docetaxel (TXT) and cisplatin (CDDP) with concurrent thoracic radiotherapy (TRT) for locally advanced non-small-cell lung cancer (LA-NSCLC)
74. Accelerated radiotherapy with docetaxel and cisplatin as induction and concomitant chemotherapy for stage III non-small cell lung cancer
75. Long-term survival after concurrent cisplatin/etoposide (PE) plus chest radiotherapy (RT) followed by surgery in bulky, stage IIIA(N2) and IIIB non-small cell lung cancer (NSCLC): 6-year outcomes from Southwest Group Study 8805
76. Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small cell lung cancer
77. Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small cell lung cancer: Mature results of a Phase II trial
78. Impact of preoperative bimodality induction including twice-daily radiation on tumor regression and survival in stage III non-small cell lung cancer
79. Neoadjuvant chemoradiotherapy prior to surgery for stage IIIA Non-small cell lung carcinoma (NSCLC): A nonrandomized comparison of carboplatin/paclitaxel to etoposide/cisplatin
80. Neoadjuvant paclitaxel-carboplatin plus irradiation (XRT) improves resectability and local-regional control over neoadjuvant paclitaxel alone for stage IIIA non-small cell lung carcinoma (NSCLC)
81. Accelerated fractionation radiation (AFR), concurrent paclitaxel/cisplatin chemotherapy and surgery for stage III non-small cell lung cancer
82. Induction chest radiotherapy (RT) with weekly paclitaxel and carboplatin in marginally resectable non-small cell lung cancer (NSCLC)
83. Promising new developments in cancer chemotherapy
84. In vitro characterization of BMS-184476, a novel taxane with promising preclinical activity
85. Phase I and pharmacokinetic (PK) study of BMS-184476, a new taxanes analog, given weekly in patients with advanced malignancies
86. Phase I and pharmacokinetic (PK) study of BMS-184476, a potent and soluble taxane analog, as a 1-hour infusion every 3 weeks
87. Phase I clinical and pharmacokinetic study of the taxanes analog BMS-184476 administered as a 1-hour iv infusion in combination with carboplatin every 21 days
88. In vitro efficacy of a novel chemoradiopotentiator - Taxoltere metro
89. Phase I study of Taxoprexin Dha-paclitaxel (Txp), a novel taxanes with unique preclinical activity, pharmacology, and toxicity profile
90. Preclinical oral antitumor activity of BMS-185660, a paclitaxel derivate
91. New therapeutic strategies for lung cancer: Biology and molecular biology come of age
92. Sensitization of HER-2/neu-over-expressing non-small cell lung cancer cell to chemotherapeutic drugs by tyrosine kinase inhibitor emodin
93. Enhancement of drug sensitivity of human malignancies by epidermal growth factor
94. Monoclonal antibody to HER-2/neu receptor modulates repair of radiation induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene
95. Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations
96. Beta-tubulin mutations in circulating extracellular DNA of non-small cell lung cancer (NSCLC) patients (pts)
97. Phase II study of docetaxel with simultaneous radiochemotherapy in patients with locally advanced non-resectable non-small cell lung cancer (NSCLC) - Preliminary results
98. Phase I study of docetaxel with concomitant thoracic radiation therapy